New hope for tough lung cancer: combo therapy enters phase II trial
NCT ID NCT07654400
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (BL-M14D1) combined with an approved immunotherapy (atezolizumab) in 36 adults with extensive-stage small cell lung cancer that has no standard treatment. The goal is to see if the combination can shrink tumors and control the disease. Participants must provide tumor samples and have a life expectancy of at least 3 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer
- New chemo combo shows promise for tough lung cancer